Michael R Kolber

Nov 16, 2024 | jdsupra.com | Michael R Kolber

This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments.

Oct 15, 2024 | cfp.ca | Samantha Moe |Sam Wong |Michael R Kolber

Clinical questionHow safe and effective are monoclonal antibodies in preventing respiratory syncytial virus (RSV) in infants? Bottom lineIn infants at high risk (born prematurely or with congenital heart or lung conditions), palivizumab (4 to 5 monthly doses during RSV season) reduces RSV hospitalization (4.4% vs 9.8% placebo). Nirsevimab (1 dose) reduces RSV hospitalizations in healthy premature infants (0.8% vs 4.1%) and term infants (0.3%-0.4% vs 1.5%-2.0%). Side effects are similar to placebo.

Sep 13, 2024 | jdsupra.com | Michael R Kolber

This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments. On August 27, the government filed a motion indicating that it intends to seek Supreme Court review of the U.S. Court of Appeals for the Fifth Circuit’s decision in Braidwood Management v. Becerra.

Jun 17, 2024 | cfp.ca | Michael R Kolber |Adrienne Lindblad |Scott W. Klarenbach |G. Michael Allan

We thank Dr Aubrey-Bassler for his comment1 pertaining to the PEER simplified lipid guideline 2023 update.2 Both the 2023 and 2015 PEER simplified lipid guidelines do not recommend repeat lipid testing for primary or secondary prevention patients, or treating to a target low-density lipoprotein level after initiation of statins.2,3 In our guideline we state, “In secondary prevention, if additional cardiovascular risk reduction is desired beyond maximized statin therapy, we recommend a...

Oct 13, 2023 | cfp.ca | Blair MacDonald |Michael R Kolber |Ricky Turgeon

Clinical questionDoes influenza vaccination reduce the risk of cardiovascular (CV) events? Bottom lineFor every 100 patients vaccinated for influenza within about 1 month of an acute coronary syndrome (ACS), 2 fewer will experience CV events and 2 fewer will die at 1 year compared with placebo. The impact of influenza vaccination in primary CV prevention and other CV conditions is less clear.